bioMérieux S.A.
ENXTPA-BIM
Company Overview
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Name
bioMérieux S.A.
CEO
Mr. Pierre Boulud
Website
www.biomerieux.com
Sector
Health Care Equipment and Supplies
Year Founded
1963
Profile
Market Cap
€12.99B
EV
€13.29B
Shares Out
118.01M
Revenue
€3,806.5M
Employees
13,696
Margins
Gross
55.72%
EBITDA
22.68%
Operating
15.41%
Pre-Tax
13.46%
Net
10.81%
FCF
4.11%
Returns (5Yr Avg)
ROA
9.48%
ROTA
17.66%
ROE
14.48%
ROCE
17.6%
ROIC
12.9%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
€116.28
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
€272.2M
Net Debt
€286.3M
Debt/Equity
0.14
EBIT/Interest
162.92
Growth (CAGR)
Rev 3Yr
5.78%
Rev 5Yr
8.54%
Rev 10Yr
8.96%
Dil EPS 3Yr
-6.76%
Dil EPS 5Yr
9.34%
Dil EPS 10Yr
11.77%
Rev Fwd 2Yr
6.97%
EBITDA Fwd 2Yr
8.36%
EPS Fwd 2Yr
23.45%
EPS LT Growth Est
10.66%
Dividends
Yield
—
Payout
24.39%
DPS
€0.85
DPS Growth 3Yr
11.09%
DPS Growth 5Yr
19.42%
DPS Growth 10Yr
9.81%
DPS Growth Fwd 2Yr
9.66%